Skip to content
WorkingMomRx
Menu

Evidence review

How Long 30 Pounds Takes on a GLP-1, Worked Against the Actual Trial Timelines

Trials report percentages; you are asking in pounds. Thirty pounds is 10% of one starting weight and 17% of another, which changes the answer entirely.

By Dana Whitfield, Managing Editora working mom, not a treating clinicianevery figure cited to its source
On this page

Why nobody gives you a straight answer

Because the question has a hidden variable in it, and it is your starting weight.

Every trial of these drugs reports results as a percentage of body weight. You are asking in pounds. Thirty pounds is not a fixed amount of progress — it is a different fraction of the job depending on where you started:

Starting weight30 lb isRoughly where that lands
180 lb16.7%Near the top of what the best trials achieved
200 lb15.0%About half of trial participants reached this
250 lb12.0%Comfortably inside the average result
300 lb10.0%Reached by about seven in ten

So a woman starting at 300 lb and a woman starting at 180 lb are asking the same question about very different tasks. The first is asking about a milestone most people pass. The second is asking about the far end of the curve.

What the trials actually measured

Three anchors, all placebo-controlled, all reporting at slightly different weeks.

DrugDurationMean weight change
Semaglutide 2.4 mg (STEP 1, n=1,961)68 weeks−14.9% vs −2.4% placebo1
Tirzepatide (SURMOUNT-1 substudy)72 weeks−21.3% vs −5.3% placebo2
Oral semaglutide 25 mg (OASIS 4, n=307)64 weeks−13.6% vs −2.2% placebo3

In absolute terms, STEP 1's semaglutide group lost 15.3 kg — about 34 pounds — against 2.6 kg on placebo1.

That is the single most useful number on this page. The average person in the largest semaglutide trial lost roughly 34 pounds, and it took about 68 weeks.

The spread matters more than the average

A mean with no distribution behind it is how this genre misleads people. STEP 1 published the distribution, and it is worth reading carefully1:

  • 86.4% lost at least 5% of their body weight
  • 69.1% lost at least 10%
  • 50.5% lost at least 15%

Turn that around. Just under a third did not reach 10%. Half did not reach 15%. These are real people on the real drug at the real dose, and the trial is not describing them as failures.

If 30 pounds is 15% of your starting weight, the honest framing is that roughly half the trial got there in 68 weeks and roughly half did not.

Why the first four months are slower than you expect

This is the part that causes the most unnecessary discouragement, and it is entirely mechanical.

You do not start on the dose that was studied. Wegovy begins at 0.25 mg weekly and steps up every four weeks — 0.25, 0.5, 1.0, 1.7, then 2.4 mg. Hold, drop, or push through walks the whole ladder, including the label's own permission to stop climbing for four weeks. That is roughly 16 weeks before you reach the maintenance dose the trial results describe. Zepbound titrates on the same four-week rhythm.

So for the first four months you are climbing toward the dose, not sitting on it. Comparing your month-two result against a headline number generated at month sixteen is comparing two different treatments.

And loss is front-loaded, not linear. People often divide 34 pounds by 68 weeks, get half a pound a week, and then panic when month five produces less than month two. That arithmetic has no biology in it. The curve is steeper early and flattens later, which means an average weekly rate describes almost no actual week.

A realistic way to think about the timeline

Not a promise — a structure, built from the trial anchors above.

  • Weeks 1–16: titration. Some loss, often modest. This phase is about tolerating the dose, not hitting a number.
  • Weeks 16–40: the steepest part of the curve for most people, once the maintenance dose is reached.
  • Weeks 40–68: flattening. Real loss continues, more slowly, and this is where most people mistake a normal plateau for failure. What happens after that window is GLP-1 maintenance and the off-ramp.
  • Around week 68: where the trial's average of roughly 34 pounds sits.

If 30 pounds is 10–12% of your body weight, you are likely to reach it well before the end of that window. If it is 16–17%, the trial data says you may be at or past the 68-week mark, and you may need tirzepatide rather than semaglutide to get there — its trial reported a mean of 21.3%2.

Five things that actually change your answer

  • Your starting weight. The single biggest variable, and the one no article about "30 pounds" accounts for.
  • Which drug. A 68-week mean of 14.9% and a 72-week mean of 21.3% are meaningfully different destinations — Zepbound vs Wegovy is the rest of that decision, and Wegovy pill vs shot covers the oral row in the table above.
  • Whether you reach the full dose. People who stop escalating early because of side effects are not on the trial's regimen.
  • Whether you are lifting. Across 20 trials and 15,782 people, resistance training was the only intervention that changed how much of the loss came from muscle rather than fat4. Preserving muscle on a GLP-1 when you're busy is the practical version.
  • Time on the drug. Every figure here is 64–72 weeks. Nobody's 12-week result is comparable to any of them — and a timeline measured in months is a cost question as much as a clinical one, which is what the cheapest GLP-1 board prices over a full year.

The short version

The average participant in the biggest semaglutide trial lost about 34 pounds in about 68 weeks, roughly a third did not reach 10%, and the first four months are spent climbing to the dose rather than living on it.

If someone quotes you a timeline in pounds without asking your starting weight, they are guessing.

Frequently asked questions

How long does it take to lose 30 pounds on Wegovy?

It depends almost entirely on your starting weight, because trials report percentages rather than pounds. In STEP 1, the average participant lost about 15.3 kg — roughly 34 pounds — over 68 weeks. If 30 pounds is 10% of your body weight you are likely to reach it well inside that window; if it is 17%, you may be at or beyond it.

Why am I losing weight so slowly in the first few months?

Because you are not yet on the dose the trials studied. Wegovy starts at 0.25 mg and steps up every four weeks through 0.5, 1.0 and 1.7 mg before reaching 2.4 mg — roughly 16 weeks of titration. Zepbound uses the same four-week rhythm. Comparing a month-two result to a headline figure generated at month sixteen compares two different treatments.

How many pounds per week should I expect to lose on a GLP-1?

Weekly averages are misleading here because loss is front-loaded rather than linear. Dividing a 68-week total by 68 produces a number that describes almost no actual week, and it tends to make people think they are failing during the normal flattening later in the course.

Does everyone lose 15% on semaglutide?

No. In STEP 1, 86.4% of participants lost at least 5% of their body weight, 69.1% lost at least 10%, and 50.5% lost at least 15%. Just under a third did not reach 10%. Those were people taking the real drug at the full dose.

Is tirzepatide faster than semaglutide for losing 30 pounds?

The trial averages differ meaningfully — 21.3% at 72 weeks in the SURMOUNT-1 substudy against 14.9% at 68 weeks in STEP 1. These are separate trials rather than a head-to-head comparison, so the gap is suggestive rather than measured, but if your 30 pounds represents a large share of your body weight it is a relevant difference to raise.

Where this leaves you

Read the Trava Health review →Read the RxPros review →Read the AquaVita NextGen review →See Best GLP-1 for busy moms — the whole scorecard →

References

  1. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1; n = 1,961; −15.3 kg vs −2.6 kg; 86.4% lost ≥5%, 69.1% ≥10%, 50.5% ≥15% at week 68). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
  2. Look M, Dunn JP, Kushner RF, Cao D, Harris C, Gibble TH, Stefanski A, Griffin R (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight (DXA substudy, n = 160 of 2,539; several authors employed by Eli Lilly). Diabetes, Obesity and Metabolism. https://pubmed.ncbi.nlm.nih.gov/39996356/
  3. Wharton S, Lingvay I, Bogdanski P, Duque do Vale R, Jacob S, Karlsson T, Shaji C, Rubino D, Garvey WT (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4; n = 307; funded by Novo Nordisk). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/40934115/
  4. Eisa N, Barood O (2026). Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials (20 RCTs, 15,782 participants). Diabetes, Obesity and Metabolism. https://pubmed.ncbi.nlm.nih.gov/41877354/

Read this as information, not instructions. WorkingMomRx is educational and never a diagnosis, a treatment plan, or a reason to start or stop a medication. A GLP-1 is a clinical decision — run it past a licensed clinician who knows your history before you act on anything here.

Continue reading